Unknown

Dataset Information

The evolving landscape of antiemetic prophylaxis for chemotherapy-induced nausea and vomiting: inspiration from cisplatin-based antiemetic and non-antiemetic trials.


ABSTRACT:

Background

Despite the significant advancements in antiemetic regimens for preventing chemotherapy-induced nausea and vomiting (CINV), over 40% of cancer patients undergoing chemotherapy still experience CINV in clinical practice. To figure out underlying reasons and outline the landscape of antiemetic prophylaxis for CINV, our focus centered on cisplatin, one of the most commonly used highly emetogenic chemotherapy drugs. We aimed to elucidate trends in CINV management by analyzing data extracted from cisplatin-based clinical trials.

Methods

We extracted CINV-related data from 156 eligible randomized clinical trials, comprising 39 antiemetic trials and 117 non-antiemetic trials, all with patients undergoing high-dose cisplatin-based chemotherapy. Subsequently, we conducted

SUBMITTER: Sun Y 

PROVIDER: S-EPMC11599296 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature